NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.89% | 3.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.89% | 3.98% | |||
| Cost of Revenue | 18.48% | -8.09% | |||
| Gross Profit | -9.54% | 7.54% | |||
| SG&A Expenses | -28.12% | 39.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.75% | 19.46% | |||
| Operating Income | 39.27% | -94.29% | |||
| Income Before Tax | 45.12% | -155.76% | |||
| Income Tax Expenses | -62.45% | 19.27% | |||
| Earnings from Continuing Operations | 47.94% | -115.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.94% | -115.64% | |||
| EBIT | 39.27% | -94.29% | |||
| EBITDA | 43.02% | -104.55% | |||
| EPS Basic | 48.79% | -115.19% | |||
| Normalized Basic EPS | 63.38% | -276.32% | |||
| EPS Diluted | 48.80% | -115.23% | |||
| Normalized Diluted EPS | 63.38% | -276.32% | |||
| Average Basic Shares Outstanding | 1.67% | 0.21% | |||
| Average Diluted Shares Outstanding | 1.67% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||